Application of the CO breath test to explore the reversibility of hyperglycemia's impact on erythrocyte lifespan.

IF 3.4 4区医学 Q1 BIOCHEMICAL RESEARCH METHODS

Journal of breath research Pub Date : 2025-09-17 DOI:10.1088/1752-7163/adfe0d

Chen-Fang Song, Yong-Jian Ma, Yong-Qiang Ji, Liang-Ling Cai, Fei Zhao, Yuan-Yi Feng, Jia-Ting Lin, Zhen-He Huang

{"title":"Application of the CO breath test to explore the reversibility of hyperglycemia's impact on erythrocyte lifespan.","authors":"Chen-Fang Song, Yong-Jian Ma, Yong-Qiang Ji, Liang-Ling Cai, Fei Zhao, Yuan-Yi Feng, Jia-Ting Lin, Zhen-He Huang","doi":"10.1088/1752-7163/adfe0d","DOIUrl":null,"url":null,"abstract":"Hyperglycemia can shorten red blood cell (RBC) lifespan, leading to incorrectly measured glycated hemoglobin (HbA1c) values. Correcting for the impact of the RBC lifespan on HbA1c is a critical issue in clinical practice. Before establishing a generally accepted correction formula to account for the impact of RBC lifespan on HbA1c, it is necessary to investigate the duration necessary to emake the hyperglycemia-induced RBC lifespan shortening reverse to normal. This longitudinal clinical trial examined the RBC lifespan in 31 hospitalized patients with type 2 diabetes mellitus by measuring the concentration of exhaled endogenous carbon monoxide. The 31 non-smoking patients with type 2 diabetes were all admitted due to blood glucose (BG) imbalance, and their RBC lifespan was tested at admission, discharge (after ∼2 weeks of intensive glycemic control), and 3 months after discharge. During the period from admission to three months after discharge, RBC lifespan significantly increased in the patients as they underwent drug treatment to control BG (P< 0.05) effectively. HbA1c, fasting plasma glucose, and 2 h postprandial glucose decreased significantly. This study found that (i) a shortened RBC lifespan caused by hyperglycemia is reversible, and (ii) the time required for this reversal is three months of effective drug treatment to control BG.","PeriodicalId":15306,"journal":{"name":"Journal of breath research","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of breath research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1088/1752-7163/adfe0d","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}

引用次数: 0

Abstract

Hyperglycemia can shorten red blood cell (RBC) lifespan, leading to incorrectly measured glycated hemoglobin (HbA1c) values. Correcting for the impact of the RBC lifespan on HbA1c is a critical issue in clinical practice. Before establishing a generally accepted correction formula to account for the impact of RBC lifespan on HbA1c, it is necessary to investigate the duration necessary to emake the hyperglycemia-induced RBC lifespan shortening reverse to normal. This longitudinal clinical trial examined the RBC lifespan in 31 hospitalized patients with type 2 diabetes mellitus by measuring the concentration of exhaled endogenous carbon monoxide. The 31 non-smoking patients with type 2 diabetes were all admitted due to blood glucose (BG) imbalance, and their RBC lifespan was tested at admission, discharge (after ∼2 weeks of intensive glycemic control), and 3 months after discharge. During the period from admission to three months after discharge, RBC lifespan significantly increased in the patients as they underwent drug treatment to control BG (P< 0.05) effectively. HbA1c, fasting plasma glucose, and 2 h postprandial glucose decreased significantly. This study found that (i) a shortened RBC lifespan caused by hyperglycemia is reversible, and (ii) the time required for this reversal is three months of effective drug treatment to control BG.

查看原文本刊更多论文

应用一氧化碳呼吸试验探讨高血糖对红细胞寿命影响的可逆性。

高血糖会缩短红细胞（RBC）寿命，导致糖化血红蛋白（HbA1c）值测量不正确。纠正红细胞寿命对HbA1c的影响是临床实践中的一个关键问题。在建立一个被普遍接受的校正公式来解释红细胞寿命对HbA1c的影响之前，有必要研究使高血糖诱导的红细胞寿命缩短逆转到正常所需的时间。本纵向临床试验通过测量呼出的内源性一氧化碳浓度来检测31例住院2型糖尿病患者的红细胞寿命。31例非吸烟2型糖尿病患者均因血糖不平衡入院，分别于入院、出院（强化血糖控制~2周后）、出院后3个月检测RBC寿命。入院至出院后3个月期间，患者接受药物治疗有效控制血糖，RBC寿命明显延长（P < 0.05）。HbA1c、空腹血糖（FPG）、餐后2小时血糖（2hPG）均显著降低。本研究发现：(1)高血糖导致的红细胞寿命缩短是可逆的，(2)这种逆转需要三个月的有效药物治疗来控制血糖。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of breath research BIOCHEMICAL RESEARCH METHODS-RESPIRATORY SYSTEM

CiteScore

7.60

自引率

21.10%

发文量

审稿时长

>12 weeks

期刊介绍： Journal of Breath Research is dedicated to all aspects of scientific breath research. The traditional focus is on analysis of volatile compounds and aerosols in exhaled breath for the investigation of exogenous exposures, metabolism, toxicology, health status and the diagnosis of disease and breath odours. The journal also welcomes other breath-related topics. Typical areas of interest include: Big laboratory instrumentation: describing new state-of-the-art analytical instrumentation capable of performing high-resolution discovery and targeted breath research; exploiting complex technologies drawn from other areas of biochemistry and genetics for breath research. Engineering solutions: developing new breath sampling technologies for condensate and aerosols, for chemical and optical sensors, for extraction and sample preparation methods, for automation and standardization, and for multiplex analyses to preserve the breath matrix and facilitating analytical throughput. Measure exhaled constituents (e.g. CO2, acetone, isoprene) as markers of human presence or mitigate such contaminants in enclosed environments. Human and animal in vivo studies: decoding the ''breath exposome'', implementing exposure and intervention studies, performing cross-sectional and case-control research, assaying immune and inflammatory response, and testing mammalian host response to infections and exogenous exposures to develop information directly applicable to systems biology. Studying inhalation toxicology; inhaled breath as a source of internal dose; resultant blood, breath and urinary biomarkers linked to inhalation pathway. Cellular and molecular level in vitro studies. Clinical, pharmacological and forensic applications. Mathematical, statistical and graphical data interpretation.